Abstract Library

#4231 Analysis of AI-based clinical trial search tool usage reveals motivations of neuroendocrine tumors patients in searching for trials

Introduction: It is challenging to recruit neuroendocrine tumors (NETs) patients to clinical trials. Delays in trial recruitment are detrimental to progress in clinical research. One potential reason for delays is that many patients report not being offered trials.

Conference:

Presenting Author: Mailman J

Authors: Ralic D, Mailman J,

Keywords: AI, patient engagement, clinical research, NET, clinical trials,

#4228 Evaluation of the impact of indoleamine 2,3-deoxygenase (IDO) enzyme activity in neuroendocrine tumors (NETs)

Introduction: Indoleamine 2,3-deoxygenase (IDO) enzyme, by inducing L-tryptophan (Trp) depletion and L-kynurenine (kyn) accumulation, contributes to the formation of an immunosuppressive microenvironment. Some studies highlighted that patient with cancer in treatment with immune checkpoint inhibitors (ICI) and with low Kyn/Trp values showed a better PFS and OS, but there are no data for NETs.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Mazzilli R, Zamponi V, Motta C, Salerno G,

Keywords: neuroendocrine tumor, IDO enzyme, Kyn/Trp ratio, immunotherapy,

#4214 Splenic metastases in the course of neuroendocrine tumors – Are they really that uncommon?

Introduction: Splenic metastases are described as exceptional in the literature. Their frequency is low regardless of the type of neoplasm. In the course of neuroendocrine tumors (NETs), spleen involvement seems infrequent too. There is only a limited number of case reports of such presentation.

Conference:

Presenting Author:

Authors: Maciejewski A, Komarnicki P, Wietrzyk D, Musiałkiewicz J, Woliński K,

Keywords: NETs, metastases, spleen, clinical course,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#4192 Real-world efficacy and safety of re-treatment with [177Lu] Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)

Introduction: The established efficacy and safety of [177Lu]-DOTA-TATE in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and bronchial NETs (G1, G2) have paved the way for exploration into re-treatment ([177Lu] RR-PRRT) safety and efficacy, an area with limited available data.

Conference:

Presenting Author: Martinez Lago N

Authors: Martinez Lago N, Hernando Cubero J, Calatayud A, Velazquez F, Anido U,

Keywords: Re-treatment, PRRT, neuroendocrine, 177Lu,